PATTIES FOODS - Asset Resilience Ratio
PATTIES FOODS (PH4) has an Asset Resilience Ratio of 12.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PATTIES FOODS total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how PATTIES FOODS's Asset Resilience Ratio has changed over time. See what is PATTIES FOODS's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down PATTIES FOODS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PATTIES FOODS market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €165.00 Million | 12.15% |
| Total Liquid Assets | €165.00 Million | 12.15% |
Asset Resilience Insights
- Moderate Liquidity: PATTIES FOODS has 12.15% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
PATTIES FOODS Industry Peers by Asset Resilience Ratio
Compare PATTIES FOODS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for PATTIES FOODS (2020–2025)
The table below shows the annual Asset Resilience Ratio data for PATTIES FOODS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.15% | €165.00 Million ≈ $192.90 Million |
€1.36 Billion ≈ $1.59 Billion |
-8.31pp |
| 2024-12-31 | 20.45% | €285.00 Million ≈ $333.19 Million |
€1.39 Billion ≈ $1.63 Billion |
+18.65pp |
| 2023-12-31 | 1.81% | €30.00 Million ≈ $35.07 Million |
€1.66 Billion ≈ $1.94 Billion |
-27.70pp |
| 2022-12-31 | 29.50% | €483.41 Million ≈ $565.15 Million |
€1.64 Billion ≈ $1.92 Billion |
-13.80pp |
| 2021-12-31 | 43.30% | €983.62 Million ≈ $1.15 Billion |
€2.27 Billion ≈ $2.66 Billion |
+33.50pp |
| 2020-12-31 | 9.81% | €369.00 Million ≈ $431.39 Million |
€3.76 Billion ≈ $4.40 Billion |
-- |
About PATTIES FOODS
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more